vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and dLocal Ltd (DLO). Click either name above to swap in a different company.
dLocal Ltd is the larger business by last-quarter revenue ($337.9M vs $196.0M, roughly 1.7× Axsome Therapeutics, Inc.). dLocal Ltd runs the higher net margin — 16.5% vs -14.6%, a 31.0% gap on every dollar of revenue. On growth, dLocal Ltd posted the faster year-over-year revenue change (65.2% vs 65.0%). dLocal Ltd produced more free cash flow last quarter ($99.8M vs $-18.7M).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
dLocal Limited is a Uruguayan financial technology company. It provides cross-border payments connecting global merchants to emerging markets.
AXSM vs DLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $337.9M |
| Net Profit | $-28.6M | $55.6M |
| Gross Margin | — | 34.3% |
| Operating Margin | -13.8% | 18.6% |
| Net Margin | -14.6% | 16.5% |
| Revenue YoY | 65.0% | 65.2% |
| Net Profit YoY | 61.9% | 87.3% |
| EPS (diluted) | $-0.55 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $337.9M | ||
| Q3 25 | $171.0M | $282.5M | ||
| Q2 25 | $150.0M | — | ||
| Q1 25 | $121.5M | — | ||
| Q4 24 | $118.8M | $204.5M | ||
| Q3 24 | $104.8M | $185.8M | ||
| Q2 24 | $87.2M | — | ||
| Q1 24 | $75.0M | — |
| Q4 25 | $-28.6M | $55.6M | ||
| Q3 25 | $-47.2M | $141.3M | ||
| Q2 25 | $-48.0M | — | ||
| Q1 25 | $-59.4M | — | ||
| Q4 24 | $-74.9M | $29.7M | ||
| Q3 24 | $-64.6M | $90.8M | ||
| Q2 24 | $-79.3M | — | ||
| Q1 24 | $-68.4M | — |
| Q4 25 | — | 34.3% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 40.9% | ||
| Q3 24 | — | 42.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -13.8% | 18.6% | ||
| Q3 25 | -27.0% | 19.7% | ||
| Q2 25 | -24.5% | — | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | 20.7% | ||
| Q3 24 | -59.8% | 22.1% | ||
| Q2 24 | -89.5% | — | ||
| Q1 24 | -89.7% | — |
| Q4 25 | -14.6% | 16.5% | ||
| Q3 25 | -27.6% | 50.0% | ||
| Q2 25 | -32.0% | — | ||
| Q1 25 | -48.9% | — | ||
| Q4 24 | -63.1% | 14.5% | ||
| Q3 24 | -61.7% | 48.9% | ||
| Q2 24 | -91.0% | — | ||
| Q1 24 | -91.1% | — |
| Q4 25 | $-0.55 | $0.18 | ||
| Q3 25 | $-0.94 | $0.17 | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | $0.09 | ||
| Q3 24 | $-1.34 | $0.09 | ||
| Q2 24 | $-1.67 | — | ||
| Q1 24 | $-1.44 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $719.9M |
| Total DebtLower is stronger | — | $86.7M |
| Stockholders' EquityBook value | $88.3M | $569.4M |
| Total Assets | $689.8M | $1.5B |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $719.9M | ||
| Q3 25 | $325.3M | $604.5M | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | $425.2M | ||
| Q3 24 | $327.3M | $560.5M | ||
| Q2 24 | $315.7M | — | ||
| Q1 24 | $331.4M | — |
| Q4 25 | — | $86.7M | ||
| Q3 25 | — | $63.1M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $39.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $88.3M | $569.4M | ||
| Q3 25 | $73.7M | $504.7M | ||
| Q2 25 | $73.1M | — | ||
| Q1 25 | $53.2M | — | ||
| Q4 24 | $57.0M | $489.0M | ||
| Q3 24 | $92.9M | $457.0M | ||
| Q2 24 | $102.9M | — | ||
| Q1 24 | $144.0M | — |
| Q4 25 | $689.8M | $1.5B | ||
| Q3 25 | $669.3M | $1.4B | ||
| Q2 25 | $639.8M | — | ||
| Q1 25 | $596.7M | — | ||
| Q4 24 | $568.5M | $1.2B | ||
| Q3 24 | $561.5M | — | ||
| Q2 24 | $548.2M | — | ||
| Q1 24 | $545.7M | — |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $100.4M |
| Free Cash FlowOCF − Capex | $-18.7M | $99.8M |
| FCF MarginFCF / Revenue | -9.6% | 29.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $378.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $100.4M | ||
| Q3 25 | $1.0M | $315.0M | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.4M | — | ||
| Q4 24 | $-26.2M | $-141.1M | ||
| Q3 24 | $-18.6M | $108.3M | ||
| Q2 24 | $-30.1M | — | ||
| Q1 24 | $-53.5M | — |
| Q4 25 | $-18.7M | $99.8M | ||
| Q3 25 | $988.0K | $313.4M | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | $-141.6M | ||
| Q3 24 | $-18.7M | $107.1M | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-53.6M | — |
| Q4 25 | -9.6% | 29.5% | ||
| Q3 25 | 0.6% | 110.9% | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | -69.2% | ||
| Q3 24 | -17.9% | 57.6% | ||
| Q2 24 | -34.6% | — | ||
| Q1 24 | -71.4% | — |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 1.80× | ||
| Q3 25 | — | 2.23× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -4.75× | ||
| Q3 24 | — | 1.19× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
